AzurRx BioPharma Inc. (NASDAQ: AZRX) stock gained by 3.17% in the last trading close while the AZRX stock rises by 11.54% in the pre-market trading session. AzurRx BioPharma is a clinical-stage biopharmaceutical company focused on developing non-systemic, effective treatments for gastrointestinal (GI) diseases. Three gut-restricted GI assets are in the queue for the venture.
Recent Past Development
AzurRx on March 22, 2021, announced that it has completed enrollment in its Phase 2 study analyzing MS1819 in conjunction with the existing standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the counter of serious exocrine pancreatic insufficiency (EPI) in cystic fibrosis patients.
The CEO James Sapirstein said that it has been concluded that the combination therapy has great potential to benefit the 25-30% of refractory cystic fibrosis patients with extreme EPI who are unable to obtain sufficient nutrition using PERT alone, based on the very promising clinical findings to date. With an improved safety profile, adding a small dose of MS1819 will help these patients fulfill their nutritional needs, reduce the debilitating symptoms of EPI, and improve their overall quality of life.
Insight of Phase 2 Trial
The MS1819 Phase 2 combination clinical trial is a multi-center investigation into the safety, immunogenicity, and usefulness of escalating doses of MS1819 in combination with a stable dose of PERT to raise the patient’s coefficient of fat absorption (CFA) levels and alleviate abdominal symptoms. The research involved 18 patients with extreme EPI who were at least 12 years old. In addition to their normal PERT dose, patients in the study receive escalating doses of MS1819 of 700mg, 1200mg, and 2240mg once daily for 15 days per dosing stage.
Since AzurRx itself has not released any update on the current rise in AZRX stock therefore we can only assume that this recent development in the phase 2 combination clinical trial is attracting the attention of investors towards the AZRX shares.